US Patent

US9730900 — Transdermal estrogen device and delivery

Method of Use · Assigned to Noven Pharmaceuticals Inc · Expires 2028-07-10 · 2y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of using transdermal drug delivery systems for the administration of estrogen.

USPTO Abstract

Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.

Drugs covered by this patent

Estrace (ESTRADIOL) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2086`	—	Estrace
`U-2086`	—	Estrace
`U-2086`	—	Estrace
`U-2086`	—	Estrace
`U-2086`	—	Estrace

Patent Metadata

Patent number: US9730900
Jurisdiction: US
Classification: Method of Use
Expires: 2028-07-10
Drug substance claim: No
Drug product claim: No
Assignee: Noven Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.